All results

1 results for phase 2 multi center double blind randomized dose ranging placebo controlled study

• TN-31 JAKPOT T1D

  A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…

  Ages

  12 Years - 35 Years

  Sexes

  All